arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ELUTIA INC.

ELUT
$0.78 ▲ +0.01 (+1.55%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
30 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
42
Health
Weak
Neutral
auto_awesome

Analytical Summary

ELUTIA INC. demonstrates solid fundamentals with strength in Return on Common Equity (%). However, watch Operating Margin (%) which shows concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $34.5M
Dividend Yield —
Revenue Growth -61.2% ↘
Op. Margin -327.9% ↘
ROIC -50.6% ↘
FCF / Share $-0.19 →
Trailing P/E —
Price / Book 2.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.43M
↓ -61.2% —
Net Income Profit after all expenses
$-7.65M
↑ +20.4% —
Operating Margin Operating profit as % of sales
-327.9%
↓ -60.8% 0th
FCF / Share Free cash flow per share
$-0.19
— -0.3% —
Long-Term Debt Long-term obligations
$26.10M
↑ +3.9% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns
100
Financial Health ↑
39
Cash Quality
11

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 30 quarters